Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term **"allergen-specific immune cell"** does not refer to a single molecular entity but rather describes subsets of adaptive immune cells—primarily **B lymphocytes** and **T lymphocytes**—that are specifically reactive against particular allergens. These include: - **Allergen-specific B cells**, which produce IgE antibodies directed against specific allergens. Upon re-exposure, these antibodies trigger mast cell degranulation leading to allergic symptoms[2][4]. - **Allergen-specific CD4+ T helper cells**, which can differentiate into various subtypes including Th2-type effectors that promote IgE production and inflammation in allergic individuals, or Tr1-type regulatory T cells that suppress allergy by secreting IL‑10 and other anti-inflammatory mediators[1]. These populations are rare in peripheral blood (<1% of total B/T lymphocytes) but play central roles in both the development of allergies and the induction of tolerance during successful allergen immunotherapy. The balance between pro-allergic Th2 responses and regulatory Tr1 responses is critical for determining whether an individual develops clinical allergy or remains tolerant despite exposure[1][3]. Because "allergen-specific immune cell" is not a defined molecular target but rather a functional description encompassing multiple cellular subsets with different roles in immunity, it is not considered an appropriate therapeutic target name under standard conventions. Instead, more precise targets would be specific molecules on these subsets—such as IgE on B-cells or cytokines/receptors involved in their activation. In summary: **"Allergen-specific immune cell" is not itself a canonical molecular target but refers collectively to rare adaptive lymphocyte populations responsible for recognizing allergens. It should be replaced by more precise terms such as 'allergen‑specific CD4+ T helper 2 cell' or 'IgE-producing allergen‑specific B-cell' depending on context.[1][3]**
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allergen-specific immune cell.